Compassionate use of radiation treatment for AMD approved

Article

NeoVista's epiretinal brachytherapy has been granted a compassionate waiver by the FDA to treat advanced wet age-related macular degeneration (AMD) in a patient who was not eligible for inclusion in NeoVista's current trials of the product.

NeoVista's epiretinal brachytherapy has been granted a compassionate waiver by the FDA to treat advanced wet age-related macular degeneration (AMD) in a patient who was not eligible for inclusion in NeoVista's current trials of the product.

The patient - who was treated by Dr Carl Awh, an investigator in the Phase III CABERNET trial - had been unresponsive to standard AMD treatments, including photodynamic therapy, intravitreal steroids and anti-VEGF therapy, and was at risk of total vision loss from bilateral advanced wet AMD.

Epiretinal brachytherapy, a radiation therapy, delivers a targeted dose of strontium 90 directly to lesions up to 3 mm deep and 5.4 mm wide. NeoVista's Phase II trial, evaluating brachytherapy in combination with Avastin (bevacizumab), demonstrated an improvement in mean VA in subjects using brachytherapy plus Avastin; adverse events in the Phase II trial were limited to vitrectomy-related problems and not to radiation toxicity. The ongoing Phase III trial is investigating the safety and efficacy of NeoVista's epiretinal brachytherapy with Lucentis (ranibizumab; Novartis) versus Lucentis alone.

The success of using brachytherapy in this particular compassionate case has not yet been determined.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.